Photosensitivity

  • 20min
  • May. 2022
  • Supported by
  • La Roche-Posay

Therapeutic classes inducing this adverse event
BRAF inhibitor, Antiangiogenic agent, KIT inhibitor, Chemotherapy

Browse for more adverse events

Photosensitivity

  • 20min
  • May. 2022
  • Supported by
  • La Roche-Posay

Therapeutic classes inducing this adverse event
BRAF inhibitor, Antiangiogenic agent, KIT inhibitor, Chemotherapy

CTCAE V5.0

Painless erythema and erythema covering <10% BSA

SIMPLIFIED GRADING

Minor erythema

Painless


 

References

Peuvrel L, Cassecuel J, Bernier C, Quéreux G, Saint-Jean M, Le Moigne M, Frénard C, Khammari A, Dréno B; Supported by GESTIM Nantes group of cutaneous adverse events induced by cancer treatments. TOXICAN: a guide for grading dermatological adverse events of cancer treatments. Support Care Cancer. 2018;26:2871-7.

CTCAE V5.0

Tender erythema covering 10- 30% BSA

SIMPLIFIED GRADING

Moderate erythema OR Moderate pain (VAS <6)


 

References

Peuvrel L, Cassecuel J, Bernier C, Quéreux G, Saint-Jean M, Le Moigne M, Frénard C, Khammari A, Dréno B; Supported by GESTIM Nantes group of cutaneous adverse events induced by cancer treatments. TOXICAN: a guide for grading dermatological adverse events of cancer treatments. Support Care Cancer. 2018;26:2871-7.

CTCAE V5.0

Erythema covering >30% BSA and erythema with blistering; photosensitivity; oral corticosteroid therapy indicated; pain control indicated (e.g., narcotics or NSAIDs)

SIMPLIFIED GRADING

Severe erythema, blistering OR Severe pain (VAS ≥ 6)


 

References

Peuvrel L, Cassecuel J, Bernier C, Quéreux G, Saint-Jean M, Le Moigne M, Frénard C, Khammari A, Dréno B; Supported by GESTIM Nantes group of cutaneous adverse events induced by cancer treatments. TOXICAN: a guide for grading dermatological adverse events of cancer treatments. Support Care Cancer. 2018;26:2871-7.

CTCAE V5.0

Life-threatening consequences; urgent intervention indicated

SIMPLIFIED GRADING

Life-threatening consequences, mainly in connection with dehydration


References

Peuvrel L, Cassecuel J, Bernier C, Quéreux G, Saint-Jean M, Le Moigne M, Frénard C, Khammari A, Dréno B; Supported by GESTIM Nantes group of cutaneous adverse events induced by cancer treatments. TOXICAN: a guide for grading dermatological adverse events of cancer treatments. Support Care Cancer. 2018;26:2871-7.

Browse for more adverse events